JUST IN: New cancer drug doubles survival rates in historic breakthrough 

  A revolutionary immunotherapy drug has doubled survival time for patients battling advanced head and neck cancer, marking the most significant breakthrough in treatment for the disease in over 20 years. In findings unveiled at the prestigious American Society of Clinical Oncology (ASCO) conference, the immunotherapy drug pembrolizumab—already used in certain cancers—was shown to extend remission
The post New cancer drug doubles survival rates in historic breakthrough appeared first on TV47 Digital. Read More